Form 4: Immuneering Director Thomas Schall Increases Stake with Significant Stock Purchase

Immuneering Corp. Director Thomas J. Schall purchased 9,500 shares of Class A Common Stock for approximately $34,788, increasing his beneficial ownership to 52,885 shares.

Summary

• Thomas J. Schall, a Director of Immuneering Corp. (IMRX), acquired 9,500 shares of Class A Common Stock.
• The transaction occurred on June 27, 2025.
• The shares were purchased at a weighted average price of $3.6619 per share, with prices ranging from $3.60 to $3.73.
• The total value of the purchase was approximately $34,788.05 (9,500 shares * $3.6619).
• Following this transaction, Thomas J. Schall beneficially owns 52,885 shares of Immuneering Corp. Class A Common Stock.
• The transaction was executed pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 8

Explanation: The purchase of shares by a director is a strong positive signal, indicating confidence in the company's future performance and valuation. This aligns management's interests with shareholders.

Positives

• A Director, Thomas J. Schall, purchased 9,500 shares of Class A Common Stock, indicating confidence in the company's future prospects.
• The purchase increases the director's beneficial ownership to 52,885 shares, aligning his interests further with shareholders.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider purchase by a director of Immuneering Corp., a biotechnology company, suggests internal confidence in the company's drug development pipeline or strategic direction within the competitive biotech sector. Such transactions are often viewed by investors as a positive signal, especially in an industry where R&D success and regulatory approvals are critical value drivers.

Comparison to Industry Standards

• This document reports an insider stock purchase, which is a standard disclosure for public companies.
• There are no specific comparable companies, projects, or results mentioned to allow for a detailed comparison to industry financial or operational benchmarks.
• The transaction itself is a common occurrence in the market, reflecting an individual's investment decision rather than a company-wide performance metric.

Related Party Transactions

• The reported transaction is a related party transaction, as it involves a director of the company purchasing shares.

Stakeholder Impact

• Shareholders: The purchase by a director may be viewed positively, potentially increasing investor confidence and signaling alignment of interests between management and shareholders.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this specific transaction.

Key Dates

Recommendation

Keywords

Immuneering Corp, IMRX, Insider Purchase, Director Stock Purchase, Thomas J. Schall, SEC Form 4, Stock Acquisition, Biotechnology, Pharmaceuticals, Equity, Investment